肝细胞癌细胞免疫治疗的研究进展

肝细胞癌(HCC)的治疗目前主要采用以手术为主、配合局部放疗和化疗的综合治疗措施,但多数患者经综合治疗后也容易复发,缺乏有效的治疗药物和手段,总体治疗效果并不理想。越来越多的证据表明,肝癌的发生、发展、转移和复发与机体免疫系统有密切的关系。因此,免疫治疗特别是细胞免疫治疗可以调节机体免疫功能,诱导特异性肿瘤免疫,达到治疗肝癌、减少肝癌复发和转移的目的,已成为肝癌综合治疗的重要组成部分。对细胞免疫治疗在HCC中的临床前研究和临床试验取得的成果进行综述,并讨论当前存在的问题。

Research advances in cellular immunotherapy for primary hepatocellular carcinoma

The present therapy for primary hepatocellular carcinoma（ HCC） consists of surgery as well as local radiotherapy and chemotherapy. However,the majority of patients are susceptible to recurrence after comprehensive treatment,and the overall treatment outcome is not ideal due to the lack of effective drugs and strategies. Increasing evidence has demonstrated that the immune system is closely related to the development,progression,metastasis,and recurrence of HCC. Thus,immune therapy,especially cellular immunotherapy,could regulate immune function and induce specific antitumor immunity to achieve the goal of controlling HCC and reducing its recurrence and metastasis,which has become an essential part in the comprehensive treatment of HCC. The findings in preclinical and clinical studies on cellular immunotherapy for HCC data are reviewed,and the current problems are discussed.